Dianthus Therapeutics Inc. (DNTH) is a Healthcare · Biotechnology company listed on NASDAQ. Price $96.81 (-4.26%), Market cap $4.76B, 52-week low–high $16.86 ~ $95.76.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Financial statements, price targets, institutional (13F) holdings and related news for Dianthus Therapeutics Inc. are updated in real time on BlackAll Trade.
Dianthus Therapeutics Inc. trades at $96.81 (-4.26%). Real-time quotes and charts are available on BlackAll Trade.
Dianthus Therapeutics Inc. has a market cap of about $4.76B.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, clasepruba